United Therapeutics (UTHR) Tops Q1 EPS Views; Reaffirms Outlook
Tweet
Share
E-mailGet Alerts UTHR Hot Sheet
Price: $512.70 +0.45%
Revenue Growth %: -1.2%
Financial Fact:
Selling, general and administrative: 100.1M
Today's EPS Names:
PMCB, PLCE, DOMO, More
Revenue Growth %: -1.2%
Financial Fact:
Selling, general and administrative: 100.1M
Today's EPS Names:
PMCB, PLCE, DOMO, More
Join SI Premium – FREE
United Therapeutics (NASDAQ: UTHR) reported Q1 EPS of $1.32, $0.39 better than the analyst estimate of $0.93. Revenue for the quarter came in at $204.2 million versus the consensus estimate of $203.91 million.
United Therapeutics reaffirmed FY2012 guidance.
For earnings history and earnings-related data on United Therapeutics (UTHR) click here.
United Therapeutics reaffirmed FY2012 guidance.
For earnings history and earnings-related data on United Therapeutics (UTHR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- NIO Inc. (NIO) Tops Q2 EPS by 33c; offers guidance
- MongoDB (MDB) Tops Q2 EPS by 29c, Beats on Revenue; Offers FY37 Guidance
- Stifel Starts GlobalFoundries Inc. (GFS) at Buy, Top Pick
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
